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Objectives To [1] examine temporal trend in uptake of seasonal influenza vaccine 
(SIV) in the UK, [2] explore disease and demographic factors associated with 
vaccination.  
Methods 32,751 people with auto-immune rheumatic diseases (AIRDs) prescribed 
disease modifying anti-rheumatic drugs (DMARDs) between2006 and 2016 were 
identified from the Clinical Practice Research Datalink. The proportion vaccinated 
between 01/September of one year and 31/March of next year was calculated and 
stratified by age, other indications for vaccination, AIRD type, and number of 
DMARDs prescribed. Stata and Joinpoint regression programs were used.   
Results SIV uptake was high in those aged ≥65 years (82.3% and 80.7% in 2006-07 
and 2015-16 respectively). It was significantly lower in other age groups, but 
improved over time with 51.9% and 61.9% in the 45-64 year age group, and 32.3% 
and 50.1% in the <45 year age group being vaccinated in 2006-07 and 2015-16 
respectively. While 64.9% of the vaccinations in those ≥65 years old occurred by 3rd 
November, in time to mount a protective immune response before the influenza 
activity becomes substantial in UK, only 38.9% in the 45-64 year and 26.2% in the 
<45 year age group without any other reason for vaccination received SIV by this 
date. Women, those with additional indications for vaccination, on multiple DMARDs 
and with SLE were more likely to be vaccinated.    
Conclusion SIV uptake is low in the under 65s, and the majority of them are not 
vaccinated in time. Additional effort is required to promote timely uptake of SIV in this 
population. 
Keywords: rheumatoid arthritis, influenza, vaccination, disease modifying anti-
rheumatic drugs 
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Introduction 
Autoimmune rheumatic diseases (AIRDs) such as rheumatoid arthritis (RA) and 
systemic lupus erythematosus (SLE) associate with increased risk of influenza and 
its complications (1-4). This may be compounded by the use of potent disease 
modifying anti-rheumatic drugs (DMARDs) and biological agents (5-8). The 
European League Against Rheumatism and American College of Rheumatology 
recommend that people with AIRDs receive seasonal influenza vaccine (SIV) before 
commencing a DMARD, and annually thereafter(9, 10). In the UK, SIV is 
recommended for people older than 65 years, the immunosuppressed, and those at 
risk of influenza or its complications (11), while universal vaccination is 
recommended for adults in the USA (12).  
The uptake of SIV in people with RA, the commonest AIRD is suboptimal. For 
instance, only 23.5% people with RA in the multi-national COMORA cohort received 
SIV with substantial global variation (range 1-66.2%)(13). Higher self-reported 
vaccination rates (range 37-77%) were reported in small (n=71-155) hospital based 
surveys from the UK (14-19). Similar small (n=100-137) single-centre hospital based 
studies from other European hospitals reported uptakes of 20-48% (20-22). A 
previous study using data from the Clinical Practise Research Datalink (CPRD) 
reported that 80% of incident RA cases on DMARDs receive at least one SIV over a 
mean 5 year period, with 21-31% of the under 65s and 55-76% of those 65 years in 
age or older receiving all expected vaccinations (23) This and other small single-
centre studies mostly include people with RA, and a large study examining the 
uptake of SIV in a range of AIRDs has not been performed. Similarly, it is not known 
whether the uptake of SIV is improving, and, if people with AIRDs are vaccinated in 
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time, i.e. at least two weeks before commencement of influenza activity to allow time 
for seroconversion.  
The overall aim of this study was to determine the uptake of SIV in people with 
AIRDs treated with DMARDs.  The objectives of this study were to examine [1] the 
temporal trend in SIV uptake between 2006-7 and 2015-16 influenza seasons, [2] 
the proportion vaccinated in time before the seasonal flu virus circulates in the 
community, [3] factors associated with receiving SIV, and [4] regional variation in 
vaccination in people with AIRDs treated with DMARDs.  
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Methods 
Data source: CPRD is a longitudinal database of the UK’s general practice (GP) 
medical records incepted in 1987. In July 2013, 684 general practices were 
contributing data to CPRD for over 11 million anonymised patients (24). People 
registered in the CPRD are representative of the UK general population in terms of 
age, sex and ethnicity. CPRD includes information on demographics, lifestyle 
factors, diagnoses, medications, results of investigations and examinations, referral 
to hospitals, and prescribed medications. Diagnoses in CPRD are recorded using 
Read codes, a coded dictionary of clinical terms. The data undergo thorough quality 
checks and are of a reliable research standard with a high validity of recorded 
diagnoses, including a median proportion of cases with a confirmed diagnosis of 
89% for 183 different conditions including chronic auto-immune diseases(25). 
Validation studies also confirm high levels of completeness of clinical, diagnostic and 
prescription data  (25).  
This study was approved by the Independent Scientific Advisory Committee of the 
Medicines and Healthcare Regulatory Authority (MHRA) (Reference number: 
16_288R).   
Study population: Participants having ≥1 Read codes for RA, SLE or 
spondyloarthropathy (SpA, defined as psoriatic arthritis, reactive arthritis, 
inflammatory bowel disease associated arthritis, or ankylosing spondylitis) and at 
least one prescription of methotrexate, leflunomide, sulfasalazine, azathioprine, 
cyclosporine, mycophenolate mofetil or tacrolimus between 1st April 2006 and 31st 
March 2016 were included.  
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Identification of participants: Previously published Read code lists were used to 
identify people with RA (26, 27). Read code lists to identify participants with SLE, 
reactive arthritis, inflammatory bowel disease associated arthritis, ankylosing 
spondylitis or psoriatic arthritis were developed by GN (Post-Doctoral Research 
Fellow) AA (Rheumatologist) and CDM (General Practitioner). Similarly, product 
code lists were developed to identify prescriptions of methotrexate, leflunomide, 
sulfasalazine, azathioprine, cyclosporine, mycophenolate mofetil and tacrolimus. 
Study entry: Latest of DMARD prescription date, current registration date, or 1st 
April 2006. 
Study exit: Earliest of transfer out date, date of death, date of last data collection 
from the participants’ GP surgery or 31st March 2016 
Cohort building: The study period 1st April 2006 to 31st March 2016 was partitioned 
into 10 one-year seasonal episodes, beginning on April 1st of one year, and ending 
on March of the subsequent year. Ten separate cohorts for each influenza season 
were constructed, comprising people with AIRDs prescribed DMARD(s). Inclusion 
criteria were age ≥18 years at the start of the cohort, contributing data on the 1st 
September of that year (start of influenza season) with ≥3-month continuous 
registration at their current GP surgery prior to this date, and  DMARD prescription in 
this  period. The three-month time-lag was to allow the GP surgery time to include 
patients in any practice level at-risk register for influenza vaccination.   
Primary outcome: SIV administration was the primary outcome and was defined 
using published product and Read code lists . For participants who had more than 
one entry for SIV administration in an influenza season, the first vaccination record 
was considered valid. Vaccination status of participants who contributed data to 
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more than one influenza season returned to unvaccinated on 1st April of the 
subsequent year. Read codes for pandemic influenza vaccine were excluded as this 
study focussed on temporal trends in SIV uptake. 
Secondary outcome: SIV administration by the 3rd November, i.e. 9 weeks from 1st 
September. This would allow the individual to mount a protective immune response 
before mid-November when the influenza virus begins to circulate in the UK (11). 
Additional indications for SIV administration: Indications for SIV vary between 
countries. In the UK, SIV is indicated in those older than 65 years, and in those with 
chronic respiratory, heart, kidney, liver and neurological diseases, 
immunosuppression or diabetes as they are at a high risk of influenza and its’ 
complications (11). Therefore, for this study, participants were classified as having 
an additional indication for vaccination if they were at least 65 years old, or had 
another at-risk condition that mandates SIV administration apart from DMARD 
prescription at the start of the influenza season. At-risk conditions were defined using 
Read code lists developed by Costello et al. These encompass chronic respiratory 
diseases, chronic heart diseases, chronic kidney diseases, chronic liver diseases, 
chronic neurological diseases, diabetes, immunosuppression, and asplenia (23).   
Statistical analyses: The percentage and 95% confidence interval (CI) of 
participants who received SIV between 1st September of one year and 31st March of 
the next calendar year (i.e. start and end of influenza season) was calculated. This 
was stratified by age (<45 years, 45-64 years, ≥65 years), presence of other 
indication for SIV administration, type of AIRD (RA, SLE or SpA), and number of 
DMARDs prescribed (1 or >1) at annual-cohort entry. Percentage (95%CI) of 
vaccinations that occurred by the 3rd November of a year was calculated. The 
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cumulative weekly uptake of SIV, stratified by age-group and presence of other at-
risk conditions was plotted using cumulative frequency curves. 
Joinpoint analysis was used to determine the temporal trend in SIV uptake between 
2006-07 and 2015-16 influenza seasons. This was  stratified for age, AIRD type, and  
at-risk conditions for vaccination (11). Joinpoint uses Bayesian Information Criterion 
to generate different numbers of joinpoints indicating points in time where trends in 
SIV uptake change significantly and to fit separate linear trends in each time 
segment. Annual percentage changes (APC) for each segment, and the overall APC 
(i.e. without any model fitted) was calculated.  
Poisson regression with robust error variance was used to examine the univariate 
and multivariate associations between age, sex, AIRD type, at risk conditions for 
vaccination, number of DMARDs prescribed in the preceding 12-months  and 
receiving the SIV. A unique participant identifier was incorporated as a clustering 
term in the model  (28). Incidence rate ratios (IRR) and 95% CI were calculated. This 
analysis was repeated using data from participants exposed to methotrexate to avoid 
confounding due to DMARD potency. The uptake of SIV in each geographic regions 
of the UK during the 2015/2016 season was calculated. Poisson regression was 
used to examine the univariate and multivariate association between regions and 
SIV administration, and adjusted for age, sex, AIRD type, number of DMARDs 
prescribed, and at-risk conditions for influenza or its complications. Data 
management and analysis were performed in Stata version 14 (StataCorp, College 
Station, TX, USA).  
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Results: Data from 32,751 people with AIRDs prescribed ≥1 DMARDs between 1st 
April 2006 and 31st March 2016 were included. Their mean (SD) age at study entry 
was 58.17 (14.65) years and 65.70% were female. The mean (SD) follow-up time 
was 4.37 (3.17) years. Of those included, 24,826 (75.80%) had RA, 6,671(20.37%) 
had SpA, and 1,254 (3.83%) had SLE. 
The overall uptake of SIV increased by 2.67% (2.0%-3.4%, p<0.01) per year from 
2006 to 2013 and remained stable between 2013 and 2015 (Table 1, Figure 1, Table 
S1). On stratified analysis, the SIV uptake did not increase in the over 65s (Table 
S1). However, it increased in people aged between 45-64 years, and in those 
younger than 45 years (Table S1). 
Just under half of all vaccinations (49.89%; 95%CI (49.64%-50.14%) occurred by 
November 3rd, i.e. in time before substantial influenza activity in the UK. The 
proportion (95% CI) of vaccinations that happened in time was 64.93 (64.57-65.30)% 
in the over 65s. It was  52.85 (52.01-53.70)% and 38.89 (38.47-39.31)% in those 
aged 45-64 years with and without another at-risk condition for flu-vaccination 
respectively, and 33.22 (31.21-35.32)% and 26.18 (25.54-26.84) % in those aged 45 
years or younger, with and without  another at-risk condition  for flu-vaccination 
respectively (Figure 2). The uptake of SIV was significantly higher in those with an 
additional indication for vaccination (Figures 3, 4; Table S2, S3).  
Increasing age, female sex, presence of other at-risk conditions, and prescription of 
>1 DMARD were independently associated with SIV administration (Table 2). After 
adjusting for age, sex, study year, other at-risk conditions, and number of DMARDs 
prescribed, , SLE was significantly more, and SpA significantly less likely to be 
associated with vaccination  than RA (Table 2). These results remained unchanged 
when the analysis was restricted to influenza seasons with exposure to methotrexate 
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at the annual-cohort entry, except for a lack of association between SLE and 
vaccination status (Table S4).  
Geographic variation in SIV uptake was assessed in the latest flu season. In the 
2015/2016 influenza season, the uptake of SIV ranged between 62.58% in London 
to 77.74% in Scotland (Table S5). Using Poisson regression adjusted for age, sex, 
and  at-risk condition for flu vaccination, a statistically significant increased SIV 
uptake was observed in Northern Ireland (aIRR (95%CI) 1.16 (1.03-1.30) and 
Scotland (aIRR 1.15 (1.05-1.27) compared with the South West of England (Table 
S5).  The South West of England was used as the reference as this region had the 
median SIV uptake among all regions of the UK, 
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Discussion This nationwide primary-care study of SIV uptake over 10 years in 
people with AIRDs treated with DMARDs demonstrates an increase in uptake of SIV 
driven by improving uptake in people aged under 65 years. However, despite this, 
the uptake of SIV in individuals younger than 45 years, and in those aged between 
45-64 years without an at risk condition for vaccination remained significantly lower 
than the recommended 75% target of flu vaccination coverage for people with at-risk 
conditions(29-31). Additionally, most flu vaccinations in the under 65s did not occur 
in time i.e., 2 weeks before the flu virus begins to circulate.  
It is not possible to compare these findings to those of previous studies, since, to our 
knowledge, this is the first study to assess temporal trend in uptake of SIV among 
AIRDs and to compare uptake between different AIRDs. However, when compared 
to the national flu vaccination rates in England, the vaccine uptake in the under 65s 
in our study was higher in the year 2006-07 (national SIV uptake: 42.10% vs. SIV 
uptake in study: 44.80%) and improved further (in the year 2014-15 national SIV 
uptake: 50.30% vs. SIV uptake in study: 63.73%) (11). A similar trend was observed 
for vaccine uptake in the over 65s, with 73.9% and 71.0% people in England 
receiving SIV in 2006-07 and 2015-16 respectively, compared to 82.3% and 80.7% 
in our study for the same years. The trend towards a reduction in vaccine uptake in 
the 2015/16 influenza season observed in this study was mirrored in the nationwide 
data (11).  
The trend of increasing SIV uptake may be explained by greater public awareness, 
national campaigns, recommendations (9, 10), and efforts of rheumatology multi-
disciplinary teams in educating people with AIRDs and their GPs about the need of 
SIV(14-17). There was a substantial increase in SIV administration in the 2010-11 
and 2011-12 flu seasons, especially in the under 65 age group which could be 
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related to the pandemic flu in the year 2009-10 which increased awareness of flu 
vaccination. 
We observed that the uptake of SIV in those without an additional reason for 
vaccination has improved over the ten-year period, but is still significantly lower than 
the uptake in those 65 years or older or with other at-risk conditions (11) This 
accords with results of previous smaller studies (13-16, 18-23, 32),  and may reflect 
the fact that immunosuppressive DMARDs for which seasonal flu vaccination is 
indicated is left to individual doctors’ clinical judgement which may result in 
differential vaccine access (11). Thus, more needs to be done to improve SIV uptake 
in this age group. As flu vaccinations occur in primary care, there is a need to 
educate people with AIRDs younger than 65 years in age, as well as their GPs about 
the risks of influenza and its complications in the immunosuppressed(16, 32). Such 
interventions are likely to increase SIV uptake, as people with AIRDs cite lack of 
awareness about increased risk of influenza, need for influenza vaccination, and not 
being offered the vaccine as reasons for not being vaccinated (14-16, 18-20, 22, 32, 
33).   Strategies to improve flu-vaccination uptake include face-to-face patient 
education or provision of written educational materials (Odds Ratio (OR)s 1.11-3.33), 
and financial incentives (OR 2.22) or reminders (ORs 2.03-3.03) directed at 
healthcare professionals (HCPs) (34). Interestingly, educational outreach/feedback 
directed at HCPs did not improve uptake of SIV (OR (95%CI) 0.77 (0.72-0.81), 
whereas improving vaccine access with home visits or free vaccinations did improve 
the uptake (ORs 1.30-1.98)(34). Other factors such as having a lead HCP 
responsible for flu-vaccination in a GP surgery, robust IT-systems to identify people 
at risk of flu and its complications, reminding HCPs about SIV, and sending personal 
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invitations and reminders, including telephone reminders to patients, associated with 
improved SIV uptake in a survey of 795 GP surgeries across England (35). 
The ideal time for influenza vaccination in the UK is between September and early 
November, allowing 2 weeks for the immune response to be achieved before 
influenza activity becomes significant (11). Our results, however, reveal delayed 
uptake of vaccination, especially in the under 65s and in those without another at-
risk condition for receiving SIV. This is contrary to the findings of a claims database 
study from Germany in which 95% participants who received SIV did so by 
November(4).  Thus, people with AIRDs and their GPs should be especially 
reminded about SIV in autumn months. (35)  
The uptake of SIV was significantly higher in people aged 65 years and over, and 
was more than the target for vaccination coverage set by the Department of Health, 
European Council, and the World Health Organisation. This may be driven by the 
Quality and Outcome Framework which provides financial incentives to GP surgeries 
for administering flu vaccination to  people aged 65 years and over since the 1999-
2000 influenza season. It resulted in a substantial increase in vaccination rates 
within one year (36). Other factors such as a high burden of co-morbidities, and 
availability of time may also have contributed. A previous study from Germany also 
demonstrated increasing SIV uptake with increasing age(4).    
Our study revealed variations in the uptake of influenza vaccination according to 
AIRD type, with lower uptake in SpA. This was present on sensitivity analysis, 
restricting to influenza seasons in which a methotrexate prescription was issued. 
This suggests that greater effort should be employed to improve vaccination rates in 
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people with SpA, who are predominantly male and less likely to seek preventive 
measures.   
There are several caveats to our study. Firstly, some flu vaccinations may have been 
administered in a hospital or at work-place e.g. HCPs. This is unlikely to have a 
significant impact as SIV is administered predominantly in primary care in the UK, 
and Read codes that indicate SIV administration outside the GP surgery i.e. in a 
hospital, place of work, or privately were included in the code list. Moreover, we 
excluded small vessel vasculitis because of the rarity of its recording in the CPRD 
(37). Similarly, given their extremely rare use in modern rheumatology practice, we 
excluded penicillamine and gold prescriptions. Finally, the data on prescription of 
biological agents is not recorded in the CPRD, and for this reason we cannot 
compare SIV uptake in those prescribed biological and conventional DMARDs.  
However, a previous German study did not report higher SIV uptake in people on 
biological DMARDs compared to conventional DMARDs(4).    
There are several strengths of this study which include a large nationally 
representative sample size, use of a combination of diagnostic Read codes and 
DMARD prescriptions to identify immunosuppressed people with AIRDs, inclusion of 
a broad spectrum of AIRDs, and a longitudinal observation period of 10 years. Use 
of primary care prescription and consultation data minimises the risk of recall bias 
associated with questionnaire surveys. 
In summary, this study demonstrates improving but still low uptake of SIV in people 
with AIRDs younger than 65 years. Similarly, the majority of people in this age group 
are vaccinated after the seasonal flu virus begins to circulate. Thus, rheumatologists 
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and GPs should particularly educate younger people with AIRDs about the need for 
timely annual seasonal flu vaccination.  
Key messages: 
 Uptake of seasonal influenza vaccine is low in the absence of additional 
indications for vaccination. 
 Most vaccinations do not occur in time before the flu virus begins to circulate.  
 Young age seems to be an important barrier to seasonal influenza 
vaccination.   
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 Table 1: Total population and percentage (95%CI) administered seasonal influenza vaccine± between 2006 and 2016 
Year 
 
Overall Age ≥65 year 
 
Age 45-64 year 
at risk condition 
 present 
Age 45-64 year 
at risk condition  
absent  
Age <45 year 
at risk condition  
present  
Age <45 year 
at risk condition  
absent  
2006/7 
 
13,805 
61.52 (60.71-62.33) 
5,658 
82.33 (81.31-83.30) 
1,054 
69.07 (66.21-71.79) 
5,078 
48.39 (47.01-49.76) 
192 
46.35 (39.40-53.45) 
1,823 
30.77 (28.70-32.93) 
2007/8 
 
14,663 
62.11(61.32-62.89) 
6,073 
81.67 (80.68-82.63) 
1,168 
69.43 (66.73-72.01) 
5,355 
49.23 (47.89-50.56) 
191 
46.07(39.11-53.19) 
1,876 
32.62 (30.54-34.78) 
2008/9 
 
15,377 
64.04 (63.28-64.80) 
6,468 
81.79 (80.83-82.71) 
1,288 
71.12 (68.58-73.53) 
5,849 
51.76 (50.43-53.08) 
209 
48.33 (41.61-55.11) 
1,923 
36.40 (34.28-38.58) 
2009/10 
 
15,904 
64.60 (63.85-65.34) 
6,775 
80.80 (79.84-81.72) 
1,378 
69.38 (66.89-71.76) 
5,572 
53.02 (51.70-54.32) 
218 
49.08 (42.49-55.71) 
1,961 
39.93 (37.78-42.12) 
2010/11 
 
17,013 
67.10 (66.39-67.80) 
7,170 
81.72 (80.80-82.59) 
1,475 
73.02 (70.69-75.22) 
6,029 
57.62 (56.37-58.86) 
236 
58.05 (51.64-64.20) 
2,103 
41.32 (39.23-43.44) 
2011/12 
 
16,430 
71.23 (70.53-71.92) 
7,229 
82.99 (82.10-83.83) 
1,447 
76.36 (74.11-78.48) 
5,643 
62.77 (61.50-64.02) 
219 
56.62 (49.96-63.05) 
1,892 
49.31(47.06-51.57) 
2012/13 
 
16,563 
72.30 (71.61-72.78) 
7,409 
83.53 (82.67-84.36) 
1,489 
78.84 (76.70-80.85) 
5,587 
63.24 (61.96-64.49) 
224 
61.61 (55.06-67.76) 
1,854 
50.76 (48.48-53.03) 
2013/14 
 
15,879 
72.35 (71.65-73.04) 
7,236 
84.41 (83.56-85.23) 
1,571 
76.38 (74.22-78.42) 
5,140 
62.24 (60.90-63.55) 
223 
60.09 (53.51-66.33) 
1,709 
49.62 (47.25-51.99) 
2014/15 
 
14,593 
72.41 (71.68-73.13) 
 
6,784 
82.40 (81.47-83.29) 
1,373 
77.57 (75.28-79.70) 
4,786 
63.66 (62.29-65.02) 
178 
57.87 (50.47-64.92) 
1,472 
51.77 (49.21-54.31) 
2015/16 
 
12,252 
69.38 (68.55-70.19) 
5,717 
80.74 (79.70-81.74) 
1,114 
72.26 (69.56-74.81) 
4,049 
59.08 (57.55-60.58) 
135 
60.00(51.49-67.94) 
1,237 
48.99 (46.21-51.78) 
± Vaccination period taken as from 1st September to 31st March.  
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Table 2: Disease and demographic characteristics associated with seasonal 
influenza vaccine administration   
*adjuste
d for 
study 
year and 
other 
variable
s in the 
table   
  
 Crude IRR (95% CI) Adjusted IRR (95% CI) * 
Age (years)    
<45 1 1 
45-64 1.35 (1.32-1.39) 1.33 (1.29-1.36) 
≥65 1.81 (1.77-1.86) 1.73 (1.68-1.77) 
Sex   
Male 1 1 
Female 1.04 (1.03-1.06) 1.03 (1.02-1.05) 
AIRD type    
Rheumatoid arthritis 1 1 
Systemic lupus erythematosus 0.92 (0.88-0.95) 1.06 (1.02-1.10) 
Seronegative spondyloarthropathy 0.81 (0.80-0.83) 0.93 (0.92-0.95) 
Number of DMARDs   
1 1 1 
≥2 1.07 (1.05-1.09) 1.08 (1.07-1.10) 
Other influenza at-risk conditions     
Absent 1 1 
Present 1.23 (1.22-1.25) 1.12 (1.11-1.13) 
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Figure legends 
Figure 1: Percentage of people with autoimmune rheumatic diseases on disease 
modifying anti-rheumatic drugs vaccinated in each flu season from 2006 to 2016. 
Figure 2: Weekly cumulative seasonal influenza vaccine uptake between the 1st 
September and 31st March in all influenza seasons. Overall vaccine uptake was 
significantly higher in the over 65s (p<0.001) and, 45-64 (p<0.001) year age group 
with another at-risk condition for vaccination than the 45-64 year age group without 
another at-risk condition for vaccination (reference group). The latter had statistically 
similar vaccination rates as people <45 years in age with another at-risk condition for 
vaccination (p=0.267), while those younger than 45 years without another at-risk 
condition for vaccination had significantly lower vaccination uptake than the 
reference group (p<0.001).  
Figure 3: Percentage of people with autoimmune rheumatic diseases (AIRD) on 
disease modifying anti-rheumatic drugs vaccinated in each flu season from 2006 to 
2016 according to individual AIRD. 
Figure 4: Percentage of people with autoimmune rheumatic diseases (AIRD) on 
disease modifying anti-rheumatic drugs vaccinated in each flu season from 2006 to 
2016 according to number of different types of DMARDs at the start of flu season. 
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Figure 1: Percentage of people with autoimmune rheumatic diseases on disease 
modifying anti-rheumatic drugs vaccinated in each flu season from 2006 to 2016. 
 
 
Figure 2: Weekly cumulative seasonal influenza vaccine uptake between the 1st 
September and 31st March in all influenza seasons.  
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Figure 3: Percentage of people with AIRDs on DMARDs vaccinated in each flu 
season from 2006 to 2016 according to individual AIRD. 
 
Figure 4: Percentage of people with AIRDs on DMARDs vaccinated in each flu 
season from 2006 to 2016 according to number of different types of DMARDs. 
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Supplementary material  
Table S1: Annual percentage change in seasonal influenza vaccine uptake 
2006-2016  
 
Age group At risk 
conditions 
Significant 
joinpoints 
Start End APC 
Lower 
95% CI 
Upper  
95% CI 
P-value 
Overall 2013-14 2006 2013 2.7^ 2.0 3.4 <0.01 
2013 2015 -2.7 -7.7 2.5 0.20 
≥65 years* none  2006 2015 0.1 -0.2 0.5 0.40 
45-64 years + 2011-12 2006 2011 6.1^ 3.7 8.6 <0.01 
2011 2015 -0.3 -3.2 2.7 0.80 
45-64 years - none 2006 2015 1.3^ 0.1 2.6 <0.01 
28 
 
*People aged 65 years or greater in the UK are offered influenza vaccination regardless of comorbidities.  ^Indicates that the 
annual Percent change (APC) is significantly different from zero at the alpha=0.05 level 
 
 
 
 
<45 years + 2012-13 2006 2012 8.8^ 6.2 11.4 <0.01 
 2012 2015 -0.2 -4.6 4.5 0.90 
<45 years - 2012-13 2006 2012 5.4^ 2.4 8.5 <0.01 
2012 2015 -1.5 -8.7 6.3 0.60 
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Table S2: Administration of seasonal influenza vaccine according to autoimmune rheumatic disease type  
Year 
 
RA 
additional indication 
–ve 
SLE   
additional indication 
-ve 
SpA 
additional indication 
–ve 
RA 
 additional indication  
+ve 
SLE 
additional indication 
+ve 
SpA                                
additional indication 
+ve 
2006/7 4,998 
46.08(44.70-47.46) 
301 
51.50 (45.84-57.11) 
1,602 
34.96 (32.66-37.33) 
6,132 
80.06 (79.04-81.04) 
152 
68.42 (60.59-75.33) 
620 
74.52 (70.93-77.80) 
2007/8 5,176 
47.39(46.03-48.75) 
317 
50.47(44.98-55.96) 
1,738 
36.54(34.30-38.83) 
6,568 
79.57(78.57-80.53) 
164 
67.07(59.50-73.85) 
700 
74.71(71.36-77.80) 
2008/9 5,226 
50.63 (49.27-51.99) 
326 
55.21(49.77-60.54) 
1,860 
38.44(36.25-40.68) 
6,987 
79.78 (78.82-80.70) 
175 
71.43 (64.28-77.65) 
803 
75.72 (72.63-78.56) 
2009/10 5,228 
52.31 (50.96-53.67) 
331 
56.80 (51.39-62.04) 
1,974 
41.24 (39.08-43.42) 
7,299 
78.71 (77.75-79.63) 
181 
71.82 (64.82-77.91) 
891 
74.30 (71.32-77.06) 
2010/11 5,578 
56.72 (55.42-58.02) 
374 
54.01 (48.93-59.01) 
2,180 
44.82 (42.74-46.91) 
7,648 
80.19 (79.28-81.07) 
200 
75.00 (68.52-80.53) 
1,033 
76.48 (73.79-78.97) 
2011/12 5,126 
62.76 (61.43-64.07) 
319 
63.64 (58.20-68.74) 
2,090 
50.48 (48.33-52.62) 
7,617 
81.52 (80.63-82.37) 
201 
78.61 (72.38-83.75) 
1,077 
79.94 (77.44-82.23) 
2012/13 4,965 
62.69 (61.34-64.03) 
310 
60 (54.43-65.32) 
2,166 
54.25 (52.14-56.34) 
7,790 
82.76 (81.90-83.58) 
220 
80.45 (74.67-85.18) 
1,112 
78.87 (76.37-81.17) 
2013/14 4,569 
61.28 (59.86-62.69) 
271 
63.84 (57.93-69.35) 
2,009 
53.46 (51.27-55.63) 
7,678 
82.82 (81.96-83.65) 
215 
77.21 (71.11-82.34) 
1,137 
80.65 (78.25-82.85) 
2014/15 4,168 
62.24 (60.75-63.70) 
257 
66.93 (60.93-72.42) 
1,833 
56.90 (54.62-59.15) 
7,016 
81.67 (80.75-82.56) 
197 
72.59 (65.93-78.38) 
1,122 
78.88 (76.39-81.17) 
2015/16 3,463 
57.75 (56.10-59.39) 
229 
63.76 (57.31-69.74) 
1,594 
53.45 (50.99-55.89) 
5,857 
79.24 (78.18-80.26) 
161 
75.16 (67.88-81.24) 
948 
78.06 (75.31-80.58) 
RA: Rheumatoid arthritis; SLE- Systemic Lupus Erythematosus; SpA-Spondyloarthropathy. 
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Table S3: Administration of seasonal influenza vaccine stratified by number of 
prescribed DMARDs   
 
 
 
 
 
 
 
 
Year 1 DMARD, no 
additional indications 
>1 DMARD, no 
additional indications 
1 DMARD and 
additional indications 
>1 DMARD and  
additional indications 
2006/7 5,985 
42.64(41.39-43.90) 
916 
50.87(47.63-54.10) 
6,156 
79.06(78.03-80.06) 
748 
81.28(78.32-83.92) 
2007/8 6,255 
43.73(42.50-44.96) 
976 
52.56(49.42-55.68) 
6,560 
78.55(77.54-79.53) 
872 
80.96(78.22-83.44) 
2008/9 6,342 
46.61 (45.38-47.84) 
1,070 
54.67 (51.67-57.64) 
7,006 
78.69 (77.71-79.63) 
959 
82.79 (80.27-85.06) 
2009/10 6,401 
48.18 (46.96-49.41) 
1,132 
57.69 (54.78-60.54) 
7,300 
77.75 (76.78-78.69) 
1,071 
80.39 (77.90-82.66) 
2010/11 6,853 
52.05 (50.87-53.23) 
1,279 
60.67 (57.96-63.32) 
7,725 
79.28 (78.36-80.16) 
1,156 
82.09 (79.77-84.20) 
2011/12 6,379 
57.81 (56.60-59.02) 
1,156 
68.08 (65.33-70.71) 
7,745 
81.11 (80.22-81.97) 
1,150 
82.26 (79.94-84.36) 
2012/13 6,336 
58.60 (57.38-59.81) 
1,105 
68.87 (66.07-71.53) 
7,960 
82.24 (81.38-83.06) 
1,162 
82.19 (79.88-84.28) 
2013/14 5,826 
57.74 (56.47-59.00) 
1,023 
66.76 (63.82-69.59) 
7,878 
82.08 (81.21-82.91) 
1,152 
84.72 (82.53-86.69) 
2014/15 5,359 
59.82 (58.50-61.13) 
899 
67.07 (63.93-70.07) 
7,258 
80.79 (79.87-81.68) 
1,077 
83.01 (80.64-85.14) 
2015/16 4,554 
55.56 (54.11-56.99) 
732 
63.93 (60.38-67.34) 
6,092 
78.51 (77.46-79.53) 
874 
82.27 (79.59-84.66) 
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Table S4: Disease and demographic characteristics associated with seasonal 
influenza vaccine administration in patients using methotrexate  
IRR; Incident rate ratio 
*adjusted for study year and other variables in the table 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristic Crude IRR (95% CI) Adjusted IRR (95% CI)* 
Age (years)    
<45 1 1 
45-64  1.26 (1.23-1.30) 1.24 (1.21-1.28) 
≥65  1.59 (1.54-1.63) 1.53 (1.49-1.57) 
Sex   
Male 1 1 
Female 1.03 (1.01-1.04) 1.03 (1.01-1.04) 
AIRD type    
Rheumatoid arthritis  1 1 
Systemic lupus erythematosus  0.92 (0.86-0.98) 1.02 (0.95-1.08) 
Seronegative spondyloarthropathy  0.87 (0.85-0.87) 0.96 (0.94-0.98) 
Number of DMARDs   
1 1 1 
>1   1.02 (1.00-1.03) 1.03 (1.02-1.05) 
Other influenza at-risk condition      
Absent  1 1 
Present  1.18 (1.16-1.19) 1.09 (1.08-1.10) 
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Table S5: Vaccinated with seasonal influenza vaccine in the 2015/16 influenza 
season stratified by geographic region.  
Region Percentage (95% CI) 
 
Crude IRR (95% CI) Adjusted IRR (95% CI) 
≠ 
South West
§
 68.77 (65.42-71.94) 1  1 
North West England 69.27 (66.45-71.96) 1.01 (0.90-1.13) 1.00 (0.89-1.11) 
Yorkshire and 
Humber 
72.64 (63.35-80.31) 1.06 (0.83-1.34) 1.04 (0.82-1.32) 
West Midlands 64.19 (60.95-67.30) 0.93 (0.83-1.05) 0.95 (0.84-1.07) 
East Midlands - - - 
East England 65.28 (60.80-69.51) 0.95 (0.82-1.09) 0.95 (0.83-1.00) 
South Central 66.49 (64.10-68.81) 0.97 (0.87-1.07) 0.99 (0.89-1.10) 
London 62.58 (59.20-65.84) 0.91 (0.81-1.03) 0.92 (0.82-1.04) 
South East Coast 66.02 (63.69-68.27) 0.96 (0.87-1.06) 0.96 (0.87-1.07) 
Northern Ireland 76.53 (73.53-79.29) 1.11 (0.99-1.25) 1.16 (1.03-1.30) 
Scotland 77.74 (75.91-79.46) 1.13 (1.03-1.25) 1.15 (1.05-1.27) 
Wales 68.59 (66.49-70.62) 1.00 (0.90-1.10) 1.01 (0.91-1.11) 
North East England 70.97 (60.91-79.32) 1.03 (0.78-1.33) 1.00 (0.77-1.29) 
 
 § Region with a median vaccinated population  
≠ adjusted for age at start of vaccination period, sex and presence of one or more risk condition for influenza 
vaccination at start of vaccination period.  
Statistical significance determined at p<0.05 
- No data from the East Midlands region.   
 
  
 
 
 
 
 
 
 
 
 
 
